CHRS - Coherus BioSciences Appoints Rita Karachun CPA CGMA to its Board of Directors | Benzinga
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024.
Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accounting and operational aspects of the company.
"We are delighted to welcome Rita to our Board, and are confident that her impressive experience in finance, accounting, and operational transformation will be invaluable to Coherus," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "Rita's deep understanding of the promise of I-O therapies, combined with her world-class financial expertise, will serve as a vital resource as we transform our Company and advance our pipeline."
"I believe Coherus has both a solid, forward-looking vision of the innovative oncology space as well as a highly talented management team capable of successfully executing their strategic plans," said Ms. Karachun. "I joined Merck at the outset of its effort to bring innovative oncology therapies to patients, and I am thrilled to now join the Coherus Board of Directors as the Company embarks on its own journey to develop the next generation of I-O therapies aimed at extending the survival of patients with cancer."
While at Merck, Ms. Karachun served as a member of the Finance Risk Committee, responsible for global oversight of capital structure, dividend policy, insurance coverage, and more; the Enterprise Risk Management Committee, responsible for global oversight of risks, developing remediation plans, and ensuring a robust board governance process; and the Benefits Executive Oversight Committee, responsible for ...